A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

ClinicalTrials.gov ID: NCT05092347

Public ClinicalTrials.gov record NCT05092347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose Escalation and Proof-of-Concept Study of Vonsetamig (BCMA × CD3 Bispecific Antibody) for Desensitization of Chronic Kidney Disease Patients in Need of Kidney Transplantation Who Are Highly Sensitized to Human Leukocyte Antigen

Study identification

NCT ID: NCT05092347
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 56 participants

Conditions and interventions

Conditions

Chronic Kidney Disease (CKD)

Interventions

Vonsetamig Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 1, 2022
Primary completion: Nov 21, 2027
Completion: Nov 21, 2027
Last update posted: Apr 26, 2026

2022 – 2027

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Cedars-Sinai Medical Center	Los Angeles	California	90048	Recruiting
University of California Irvine	Orange	California	92868	Recruiting
Connie Frank Transplant Center at UCSF	San Francisco	California	94143	Recruiting
Yale University of Medicine	New Haven	Connecticut	06520	Recruiting
Medstar Georgetown Transplant Institute - 2-PHC	Washington D.C.	District of Columbia	20007	Recruiting
Comprehensive Transplant Center	Chicago	Illinois	60611	Recruiting
John Hopkins Hospital	Baltimore	Maryland	21224	Recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
New York University Langone Health	New York	New York	10016	Recruiting
Penn Transplant Institute	Philadelphia	Pennsylvania	19104	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05092347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 26, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05092347 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →